With the recent development of the ongoing Covid-19 pandemic, there has been increased urgency for industry and non-industry sponsors to concentrate on discovering a suitable therapeutic or vaccine for this highly contagious viral disease. Therefore, more Covid-19 clinical trials are being prepared and launched, while a vast number of clinical trials for non-Covid-19 indications are experiencing setbacks.

High profile pharmaceutical companies have declared interruptions to intended and continuing trials, delaying trial start dates and pausing subject enrolment. Read more here.